Participants' disposition
MAY
Overall, 16 patients in 10 sites in Japan were randomized in the ASCEMBL study to receive asciminib (Patient dispositionAbbreviation: NA, not applicable.Ongoing at the time of data cutoff: May 25, 2020.Patients could switch to asciminib upon meeting lack of efficacy criteria as per ELN 2013 recommendations on bosutinib.